NCT01831791 - A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

April 14, 2013

Primary Completion Date

July 19, 2014

Study Completion Date

July 19, 2014

Conditions

Alopecia

Interventions

DRUG

Dutasteride 0.5 mg

Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.

Trial Locations (5)

812-0025

GSK Investigational Site, Fukuoka

530-0057

GSK Investigational Site, Osaka

532-0003

GSK Investigational Site, Osaka

103-0028

GSK Investigational Site, Tokyo

160-0022

GSK Investigational Site, Tokyo